Get the Stockscreener App
121.33
0.25%
-0.165
Illumina Inc stock is traded at $121.33, with a volume of 176.16K.
It is down -0.25% in the last 24 hours and up +5.91% over the past month.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
See More
Previous Close:
$121.50
Open:
$120.27
24h Volume:
176.16K
Relative Volume:
0.09
Market Cap:
$18.55B
Revenue:
$4.29B
Net Income/Loss:
$703.00M
P/E Ratio:
27.18
EPS:
4.4635
Net Cash Flow:
$993.00M
1W Performance:
-5.49%
1M Performance:
+5.91%
6M Performance:
+27.42%
1Y Performance:
+43.94%
1-Day Range:
$119.68
$122.04
1-Week Range:
$119.68
$127.75
52-Week Range:
$68.70
$155.53
Illumina Inc Stock (ILMN) Company Profile
Name
Illumina Inc
Sector
Industry
Phone
(858) 202-4500
Address
5200 ILLUMINA WAY, SAN DIEGO, CA
Compare ILMN vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ILMN
Illumina Inc
|
121.34 | 18.58B | 4.29B | 703.00M | 993.00M | 4.4635 |
|
TMO
Thermo Fisher Scientific Inc
|
489.65 | 184.15B | 44.56B | 6.72B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
192.53 | 137.93B | 24.57B | 3.60B | 5.26B | 5.051 |
|
IDXX
Idexx Laboratories Inc
|
593.62 | 47.82B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
114.09 | 32.62B | 7.07B | 1.29B | 993.00M | 4.5355 |
|
WAT
Waters Corp
|
296.43 | 29.19B | 3.17B | 642.63M | 516.49M | 10.77 |
Illumina Inc Stock (ILMN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-12-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Jul-11-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Mar-04-25 | Reiterated | Citigroup | Neutral |
| Feb-28-25 | Downgrade | HSBC Securities | Buy → Hold |
| Feb-10-25 | Downgrade | Barclays | Equal Weight → Underweight |
| Feb-07-25 | Downgrade | TD Cowen | Buy → Hold |
| Dec-11-24 | Downgrade | Citigroup | Buy → Neutral |
| Nov-12-24 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-24 | Upgrade | HSBC Securities | Hold → Buy |
| Aug-28-24 | Upgrade | Argus | Hold → Buy |
| Aug-16-24 | Upgrade | Daiwa Securities | Neutral → Buy |
| Aug-14-24 | Upgrade | Barclays | Underweight → Equal Weight |
| Aug-14-24 | Upgrade | TD Cowen | Hold → Buy |
| Jul-10-24 | Upgrade | Citigroup | Neutral → Buy |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Jan-16-24 | Downgrade | HSBC Securities | Buy → Hold |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Dec-18-23 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Dec-15-23 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-11-23 | Upgrade | Citigroup | Sell → Neutral |
| Nov-10-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Sep-28-23 | Initiated | Bernstein | Underperform |
| Jul-05-23 | Resumed | JP Morgan | Neutral |
| Jan-25-23 | Downgrade | Argus | Buy → Hold |
| Jan-05-23 | Initiated | Scotiabank | Sector Perform |
| Dec-12-22 | Downgrade | Citigroup | Neutral → Sell |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Oct-04-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-28-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Neutral |
| Jul-13-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-18-22 | Upgrade | Stifel | Hold → Buy |
| Jan-11-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-07-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Aug-19-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jun-01-21 | Upgrade | Evercore ISI | Underperform → In-line |
| Mar-31-21 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Mar-31-21 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-03-21 | Initiated | Barclays | Underweight |
| Dec-22-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-17-20 | Upgrade | BTIG Research | Neutral → Buy |
| Oct-13-20 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-30-20 | Initiated | Atlantic Equities | Overweight |
| Sep-29-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-22-20 | Downgrade | Stifel | Buy → Hold |
| Sep-22-20 | Downgrade | UBS | Buy → Neutral |
| Sep-21-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-21-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-07-20 | Downgrade | Evercore ISI | In-line → Underperform |
| Aug-07-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-07-20 | Downgrade | Guggenheim | Buy → Neutral |
| Apr-24-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-21-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-08-20 | Initiated | Wells Fargo | Underweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-15-19 | Initiated | Stifel | Buy |
| Oct-25-19 | Initiated | Guggenheim | Buy |
View All
Illumina Inc Stock (ILMN) Latest News
Schroder Investment Management Group Sells 66,235 Shares of Illumina, Inc. $ILMN - MarketBeat
First Trust Advisors LP Sells 89,600 Shares of Illumina, Inc. $ILMN - MarketBeat
Illumina partnership aims to speed rare disease diagnosis in Florida - AADC News
Illumina Stock Climbs 44.8% in a Year: What's Driving the Rally? - The Globe and Mail
Bioinformatics Market to Reach US$ 29.1 Billion by 2031 Growing - openPR.com
Capital International Inc. CA Boosts Stake in Illumina - National Today
Capital International Inc. CA Boosts Stock Holdings in Illumina, Inc. $ILMN - MarketBeat
Inceptionr LLC Invests in Illumina, Inc. - National Today
Here’s Why Illumina Stock Could Continue Its 44% Recovery Into 2026 - TIKR.com
Capital World Investors Acquires 3,331,542 Shares of Illumina, Inc. $ILMN - MarketBeat
Capital International Sarl Buys 24,055 Shares of Illumina, Inc. $ILMN - MarketBeat
Illumina, Inc. $ILMN Stock Holdings Increased by Capital International Ltd. CA - MarketBeat
Epigenetics Market to Reach US$ 7.10 Billion by 2033 at 14.8% CAGR - openPR.com
Inceptionr LLC Makes New Investment in Illumina, Inc. $ILMN - MarketBeat
Molecular Diagnostics Market Outlook: Set to Grow at 10%+ CAGR Through 2031 as Precision Medicine and Genetic Testing Advance, Says Mordor Intelligence - GlobeNewswire Inc.
How Singapore is solidifying its role at the forefront of global genomics - Illumina
Here's Why Illumina (ILMN) is a Strong Momentum Stock - Yahoo Finance
Neuberger Berman Group LLC Purchases 8,135 Shares of Illumina, Inc. $ILMN - MarketBeat
Neo Ivy Capital Management Invests $1.83 Million in Illumina, Inc. $ILMN - MarketBeat
Illumina Regeneron Alliance Targets Multiomics And Raises Valuation Questions - Yahoo Finance UK
Illumina, Inc. and Nashville Biosciences, LLC Announce New Proteomics Data Offering and Expansion of Alliance for Genomic Discovery Dataset - marketscreener.com
Alliance for Genomic Discovery expands with Regeneron Genetics Center membership and new proteomics data offering - Illumina
Illumina (ILMN) Gaining from Stronger Than Expected Results - Insider Monkey
How Illumina Inc. (ILMN) Affects Rotational Strategy Timing - Stock Traders Daily
TEM's Diagnostics Arm Expanding Rapidly: What's Driving the Growth? - TradingView
Integrated Quantitative Investments LLC Acquires New Holdings in Illumina, Inc. $ILMN - MarketBeat
Elo Mutual Pension Insurance Co Makes New Investment in Illumina, Inc. $ILMN - MarketBeat
ARK Investment Management Boosts Stake in Illumina - National Today
ARK Investment Management LLC Has $139.41 Million Position in Illumina, Inc. $ILMN - MarketBeat
Amova Asset Management Americas Inc. Increases Stake in Illumina, Inc. $ILMN - MarketBeat
Why Illumina (ILMN) is a Top Growth Stock for the Long-Term - Nasdaq
DNA Microarray Market is expected to reach US$ 6.12 billion - openPR.com
Illumina Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
ILMN: Sequencing innovation, clinical growth, and end-to-end solutions drive strong outlook - TradingView
PacBio and DNAstack Collaborate on Global HiFi Genome Network Hub - TradingView
10,000 Shares in Illumina, Inc. $ILMN Bought by Strive Asset Management LLC - MarketBeat
ILMN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Handelsbanken Fonder AB Boosts Stake in Illumina, Inc. $ILMN - MarketBeat
Is Illumina’s (ILMN) TruPath Rare Disease Push Reframing Its Clinical Sequencing Investment Narrative? - simplywall.st
Illumina Inc. stock underperforms Monday when compared to competitors - MarketWatch
Illumina Inc (ILMN) Trading Down 2.84% on Mar 2 - GuruFocus
Illumina, Inc. (ILMN) Stock Analysis: Exploring The Upside With A 33% Return On Equity - DirectorsTalk Interviews
Why Illumina (ILMN) Is Up 14.3% After Launching TruPath Genome And Expanding Rare-Disease Sequencing - Yahoo Finance
Illumina: Competitive Pressures Mounting but 2026 Revenue Targets Still Intact, Justifying a Hold Rating - TipRanks
Andra AP fonden Buys 58,209 Shares of Illumina, Inc. $ILMN - MarketBeat
Illumina, Inc. $ILMN Position Boosted by Citigroup Inc. - MarketBeat
Illumina Inc. stock outperforms competitors on strong trading day - MarketWatch
Illumina Launches TruPath Genome, Unveils NovaSeq X Roadmap, and Drives Cancer Breakthroughs with Connected MultiomicsPR Newswire APAC - PR Newswire Asia
Illumina whole-genome sequencing technology to accelerate rare disease testing in Florida - Illumina
Primecap Management Co. CA Sells 73,220 Shares of Illumina, Inc. $ILMN - MarketBeat
Evercore ISI reiterates Illumina stock rating on competitive positioning By Investing.com - Investing.com Australia
Illumina Inc Stock (ILMN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.71%
0.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):